The quest for an anti-ageing vaccine to prevent cognitive deterioration has been a long-standing goal in medicine, often considered the Holy Grail of medical research. However, recent advancements suggest that this may no longer be an unattainable dream. The key to this breakthrough lies in the development of “immune system-oriented” therapies, which work by either stimulating or suppressing the immune system to combat age-related diseases.
Researchers at the Weizmann Institute of Science in Israel are at the forefront of this research, exploring the potential of immune-targeted approaches to reduce the impact of ageing. They believe that by identifying specific proteins that trigger an immune response, it may be possible to create an anti-ageing vaccine. As they noted,
It’s exciting to imagine an immune-targeted approach to reduce the threat from our inner enemies who are causing our collapse with age. We believe that we are closer than ever to realizing these possibilities.
Ageing is associated with an imbalance in the immune system, leading to increased inflammation and the accumulation of “zombie” cells, also known as senescent cells, which remain after they should have died and been removed. These cells contribute significantly to the ageing process and are linked to various age-related diseases, including Alzheimer’s disease, atherosclerosis, and type 2 diabetes.
The concept of senolytics, or drugs that cleanse the body of these ageing cells, holds great promise. For instance, a novel vaccine targeting a protein called senescence-associated glycoprotein (SAGP) has shown significant potential in reducing amyloid plaque deposits and inflammation in the brains of mice with Alzheimer’s disease. This vaccine improved the behavior and awareness of the mice, indicating a possible way to prevent or modify the disease in humans.
In the UK, approximately one million people suffer from dementia, with around 600,000 of these cases being Alzheimer’s disease. Given that one in three people born today will develop dementia, and an estimated 2 million people are expected to be affected by 2050, finding effective treatments is crucial. Recent developments in immunotherapeutic drugs, such as Donanemab (also known as Kisunla), have raised hopes for the first successful cure for Alzheimer’s disease. This drug works by teaching immune cells to recognize and remove amyloid, a toxic protein hallmark of the disease. Donanemab has already received early-stage treatment approval in the UK.
Beyond pharmaceutical interventions, lifestyle factors such as diet and exercise have been shown to slow down the aging process. Calorie restriction, for example, can reduce brain flow to the cerebral cortex, which accelerates with age. Exercise, particularly, has been found to reduce the loss of pericytes, cells that maintain healthy blood vessels. These findings support the long-held view that ageing can be mitigated, though not overcome, through diet and exercise.
Uninterrupted sleep is another critical factor in maintaining brain function. Sleep disorders, which worsen with age, can significantly impact the brain’s ability to dispose of waste. Researchers from the University of Washington in St. Louis have highlighted the importance of sleep in preventing cognitive decline associated with ageing.
In addition to these individual factors, vaccines targeting chronic diseases are emerging as a promising approach to combat age-related disorders. Vaccines such as those against influenza, shingles, and pneumococcal infections have been associated with a reduced risk of developing Alzheimer’s disease. For instance, studies have shown that patients who received the Tdap/Td, HZ, or pneumococcal vaccine were significantly less likely to develop Alzheimer’s disease compared to their unvaccinated peers.
The immune system’s role in ageing and age-related diseases is complex and multifaceted. By understanding how to manipulate the immune response, researchers are moving closer to developing effective treatments and potentially even preventive measures for conditions like Alzheimer’s disease. The ongoing research in this field suggests that a combination of immune-targeted therapies, lifestyle modifications, and advanced vaccines may hold the key to combating the cognitive deterioration associated with ageing.
